Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap18.69B
Market cap18.69B
Price-Earnings ratio13.15
Price-Earnings ratio13.15
Dividend yield—
Dividend yield—
Average volume1.20M
Average volume1.20M
High today$133.36
High today$133.36
Low today$127.47
Low today$127.47
Open price$132.32
Open price$132.32
Volume1.24M
Volume1.24M
52 Week high$236.48
52 Week high$236.48
52 Week low$110.04
52 Week low$110.04
BIIB News
TipRanks 1d
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market InsightsBiogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...
TipRanks 5d
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...
TipRanks 5d
Biogen, Stoke Therapeutics present data from studies of zorevunersenBiogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evalua...
Analyst ratings
49%
of 37 ratingsBuy
48.6%
Hold
48.6%
Sell
2.7%
More BIIB News
Simply Wall St 6d
Biogen Insiders Sold US$1.8m Of Shares Suggesting HesitancyIn the last year, many Biogen Inc. ( ) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders...
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.